Cookie Preferences
By clicking “Accept All”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage and assist in our marketing efforts as outlined in our cookie policy.
Strictly Necessary (Always Active)
Cookies required to enable basic website functionality.
Cookies helping us understand how this website performs, how visitors interact with the site, and whether there may be technical issues.
Cookies used to deliver advertising that is more relevant to you and your interests.
Cookies allowing the website to remember choices you make (such as your user name, language, or the region you are in).

Ventures

Invest in breakthrough healthtech solutions that transform patients' lives.

00:00
/
00:00
00:00
/
00:00
Invest in transformative health innovations
Invest in transformative health innovations

We vet over 1500 innovations yearly and identify, build, and invest in 20 to 25 ventures that address crucial, unmet needs in the healthcare sector. Our ventures lead in areas such as personalized medicine, AI diagnostics, and medical devices, all of which show substantial potential for growth, return, and impact.

00:00
/
00:00
00:00
/
00:00
Invest alongside NLC
Invest alongside NLC

As an investor in an NLC venture, you always invest alongside NLC. Our team of 80+ experts offers comprehensive support to our ventures, including regulatory guidance, product development assistance, and clinical trial setup. This extensive, tailored support system de-risks your investment and enhances the likelihood of venture success. Single-company investments start at €25K.

00:00
/
00:00
00:00
/
00:00
Invest with impact
Invest with impact

By investing in one of our ventures, you help bring transformative health solutions to patients in need, directly impacting their lives. NLC is a certified B Corp and supports UN Sustainable Development Goals 3, 9, and 17, our funds are SDFR-9 compliant, which means we adhere to the strictest impact regulations. Investing in NLC ventures can be your pathway to high-impact capital deployment.

Receive the latest investment opportunities that match your interests, directly in your inbox. Stay informed and never miss out.

a highlight from our portfolio

Angiogenesis Analytics

Angiogenesis Analytics

Angiogenesis Analytics is transforming prostate cancer diagnosis by integrating artificial intelligence with advanced ultrasound technology. Our mission is to make the detection of prostate cancer quicker, more affordable, and significantly less invasive than traditional methods. By pioneering the innovative PCAVision technology, we are setting new standards in healthcare.
Visit website
Download documents
PEP Health

PEP Health

PEP Health is revolutionizing how healthcare providers understand and improve patient experiences by leveraging machine-learning technology to give healthcare organizations, regulators, and insurers the real-time, actionable insights they need to have a direct and dramatic impact on patient experiences.
Visit website
Download documents
Aerion Bioscience
Pioneering early lung cancer screening and saving lives

The challenge with lung cancer lies in its late detection, often leading to unfortunate outcomes. Current screening methods like low-dose CT scans are costly and have radiation risks, while blood tests lack accuracy or are too expensive. Our solution offers a non-invasive blood test that detects lung cancer early with high sensitivity and specificity. This test, with its multi-protein panel, can identify even stage I cancer, improving survival rates and reducing unnecessary procedures.

Active
🇱🇺 Luxembourg
Aerion Bioscience
Timelab
Software solution that enables the proactive relocation of ambulances

Timelab addresses the challenge of ambulance delays in the Netherlands by offering a proactive solution through their Emergency Mathematics software. With 7% of ambulance arrivals exceeding the 15-minute target, 35,000 patients annually don't receive timely care, impacting mortality and morbidity rates. Timelab's software predicts future demand and facilitates the proactive relocation of ambulances, aiming to reach 95% of high emergency call locations within 15 minutes, compared to the current 93%.

Active
🇳🇱 Netherlands
Timelab
Bilihome
Uncompromised bonding for newborns with wearable therapy

Bilihome aims to revolutionize jaundice treatment for newborns by bringing safe and effective phototherapy from the hospital to the comfort of home. Currently, traditional methods require babies to be isolated in hospitals, disrupting bonding and caregiving between parents and infants. Bilihome's solution integrates blue light therapy into a comfortable garment, allowing newborns to receive treatment while being held, breastfed, and cared for as usual. This patient-centered innovation enables natural care at home, freeing up hospital bed space and promoting family-centric care.

Active
🇳🇱 Netherlands
Bilihome
Ansana
A new sterilisation technology for the healthcare & pharmaceutical industry

Ansana offers a smart sterilization container for surgical instruments, designed to tackle key challenges in the healthcare sector. By integrating electronic sensors, it ensures sterility in operating rooms, reducing the risk of infections by 10% and lowering the environmental impact of sterilization processes by 85%. Ansana's enhances patient safety with real-time monitoring and traceability features, with complex instruments like endoscopes, while also cutting costs for healthcare facilities in terms of labor and materials.

Active
🇳🇱 Netherlands
Ansana
NC Biomatrix
Regeneration of intervertebral disc as treatment for low back pain

NC Biomatrix offers a solution for treating chronic back pain caused by intervertebral disc degeneration. Current treatments only address symptoms, have limited effectiveness and often come with complications. NC Biomatrix introduces a new approach using a bio-inductive protein extract obtained from porcine notochordal biomatrix. This injectable treatment addresses the underlying pathology and aims to restore the degenerated disc as a way to definitively treat chronic back pain.

Active
🇳🇱 Netherlands
NC Biomatrix
Liftya
Unique personalized shoulder assisting device

Introducing Liftya, a solution for shoulder instability. Developed with a patented spherical hinge mechanism, Liftya mimics the natural shoulder joint movement, offering stability and full range of motion. Unlike traditional braces, Liftya promotes motor recovery and independence, reducing pain and healthcare costs for patients.

Active
🇳🇱 Netherlands
Liftya
Altach
Off-the-shelf solution for improved cartilage repair

Altach is tackling the challenge of treating damaged cartilage effectively without costly or complex procedures. Altach's solution is a simple, ready-to-use implant that makes microfracture treatment better. It's made from cartilage-like material and helps the body build new, healthy cartilage. This means fewer surgeries and better outcomes for patients.

Active
🇮🇪 Ireland
Altach
Nilocas
A cardiac device for the detection of coronary artery disease

Nilocas offers a revolutionary solution for detecting coronary artery disease non-invasively and without radiation. Patients wear a lightweight chest patch that captures the sounds of turbulent blood flow through arteries using microphones and accelerometers. Advanced machine learning and AI rapidly analyze the data, providing a clear diagnosis in just 10 minutes. This innovation eliminates the need for costly and invasive procedures, making cardiac diagnosis more accessible in both clinical and non-clinical settings.

Active
🇬🇧 United Kingdom
Nilocas

Our impact

15
Countries active in
20-25
Ventures built annually
247K
Patients impacted
70+
Active ventures in our portfolio
80+
Healthcare experts
€160M+
Raised by NLC ventures

Explore our 2024 Impact report

Woman with hands in the air in nature
Maurits Schouten
00:00
/
00:00
I consider the medical sector to be very attractive. However, without the right expertise, network, and diversification, the risks can be significant. NLC removes these barriers and creates an attractive opportunity for me to participate as an investor in this sector.
Maurits Schouten

Maurits Schouten

Impact investor and Board Member of PYM

Peter Veldman
00:00
/
00:00
What I really like about NLC and what triggered my investment in the company is the strong culture and the quality of the team. NLC is able to de-risk the innovation cycle by building ventures at scale, thereby playing a leading role in shaping the future of healthcare.
Peter Veldman

Peter Veldman

Advisor and previous Deputy Head of Fund Operations at EQT Group

Invest in a portfolio of companies

A formal clothed man on a bridge in the city

Create a healthier future with us

Lars Olthof
Head of Venture Finance, Venture Investment Director